

Phospho-Insulin Receptor β (Tyr1345) Rabbit mAb[M3H6]

Cat NO. :A99525

Information:

| Applications | Reactivity: | UniProt ID: | MW(kDa) | Host | Isotype | Size |
|--------------|-------------|-------------|---------|--------|---------|-------------|
| WB | H | P06213 | 95 | Rabbit | IgG | 100ul,200ul |

Applications detail:

| Application | Dilution |
|--|-------------|
| WB | 1:1000-2000 |
| The optimal dilutions should be determined by the end user | |

Conjugate:

UnConjugate

Form:

Liquid

sensitivity:

Endogenous

Purification:

Protein A purification

Specificity:

Antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr1345 of human Insulin Receptor β

Storage buffer and conditions:

Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol (buffer) .

Shipped at 4°C. Store at -20°C or -80°C.

Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

Tissue specificity:

Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve,

Subcellular location:

Cell membrane,Single-pass type I membrane protein. Late endosome. Lysosome.

Function:

Introduction: **WB:** Western Blot **IP:** Immunoprecipitation **IHC:** Immunohistochemistry **ChIP:** Chromatin Immunoprecipitation **ICC/IF:** Immunocytochemistry/Immunofluorescence **F:** Flow Cytometry


Cross Reactivity: **H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Ml:** mink **C:** chicken **Dm** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Hr:** horse

For Research Use Only. Not For Use In Diagnostic Procedures.

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD, regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGF1 and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity)..

Validation Data:

Phospho-Insulin Receptor β (Tyr1345) Rabbit mAb[M3H6] Images



Western blot (SDS PAGE) analysis of extracts from CHO IR/IRS-1 cells overexpressing human insulin receptor, treated with insulin (100 nM for 5 min). Using Phospho-

View more information on <http://naturebios.com>

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 1% w/v Milk, 1X TBST at 4°C overnight.

For Research Use Only. Not For Use In Diagnostic Procedures.